Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a daily supplement soothe your gut? new study aims to find out

NCT ID NCT07421596

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This 8-week study is testing a dietary supplement system called PhytoPower in 50 adults with digestive issues like bloating and discomfort. Participants take the supplement daily and provide stool samples to measure changes in gut health markers. The goal is to see if the supplement improves symptoms and digestive function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PhytoPower 1 and PhytoPower 2 (dietary supplement system)
What this could lead to
If it works, this could point toward a dietary supplement that improves gut health and eases digestive symptoms like bloating and discomfort.
What could go wrong
This is a small, early-stage study with no control group, so results may not be conclusive. The supplement may not work for everyone or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Male or female adults aged 18 to 80 years (considering 50% men and 50% women, even breakdowns in age groups 18-30, 31-60, 61-80 years, and 12-15% African American required) at the time of screening. 2\. Willing and able to provide written informed consent before participation in any study-related procedures. 3\. Willing and able to comply with all study procedures, including clinic visits, completion of questionnaires, and stool sample collection at predetermined time points. 4\. Willing to collect and provide stool samples, either in-clinic or at home as instructed. 5\. Willing to abstain from alcohol consumption (including beer, wine, and spirits) for the duration of the study. 6\. Proficient in written and spoken English. 7. Willing to provide a valid email address and mobile phone number and able to complete electronic forms and questionnaires using a smartphone. 8\. Able and willing to travel to the Research Institute for in-clinic visits and stool sample collection as scheduled. 9\. No known food allergies, based on subject self-report. 10. Willing to maintain usual diet and lifestyle habits, except as required by the study protocol. 11\. Subjects with self-reported gastrointestinal symptoms, defined as a baseline Gastrointestinal Symptom Rating Scale (GSRS) score ≥ 8 (35 subjects) and score ≤ 3 (5 subjects). Exclusion Criteria: * 1\. Known allergy or hypersensitivity to any ingredient(s) of the study product or other herbal products. 2\. Presence or history of any medical condition that may interfere with study participation or outcome interpretation, including but not limited to: * Malabsorption disorders * Chronic gastrointestinal diseases * Severe depression * Clinically significant cardiovascular disease within the past 3 months 3. Pregnant, breastfeeding, or planning to become pregnant during the study period, based on subject self-report. 4\. Having a pregnant partner or a partner who is planning to become pregnant during the study period and is unwilling or unable to use an acceptable method of contraception. 5\. History of any cancer within the past 5 years. 6. Active or occasional smoking. 7. Current use of probiotics, unless willing to discontinue use at least 4 weeks prior to study enrollment. 8\. History of weight loss surgery or any type of bowel surgery, including resection or colectomy. 9\. Any active infection within the past 3 months requiring antibiotics, antiviral medication, or hospitalization. 10\. Use of immunosuppressive medications within the past 12 months, including systemic corticosteroids or biologic agents. 11\. History of seizure disorder or use of seizure medication within the past 4 weeks. 12\. History of HIV infection or solid organ transplantation. 13. Use of medications for chronic gastrointestinal or digestive conditions, including but not limited to: * Proton pump inhibitors or antacids (e.g., omeprazole, Prilosec®) * Laxatives or gastrointestinal motility agents * Medications for irritable bowel syndrome (IBS), Crohn's disease, or history of hospitalized diverticulitis 14. Any other condition that, in the opinion of the Principal Investigator, would make the subject unsuitable for participation or compromise subject safety or study integrity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Digestive health are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • San Francisco Research Institute

    RECRUITING

    San Francisco, California, 94132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.